APS.TOライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 04:59):

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States...

Stats
本日の出来高	34 400.00
平均出来高	8 958.00
時価総額	26.72M
EPS	$0 ( 2024-03-26 )
次の収益日	( $-1.010 ) 2024-05-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.160
ATR14	$0.0260 (1.53%)

Aptose Biosciences Inc 相関

10 最も正の相関
IVQ.TO	0.87
ME.TO	0.86
IVX.V	0.86
AH.TO	0.859
PYR.TO	0.859
NBVA.V	0.851
GKO.V	0.851
PLRB.V	0.847
LGD.TO	0.842
GBT.TO	0.838

10 最も負の相関
APL.V	-0.878
MAGT.TO	-0.872
SNC.TO	-0.865
URB.TO	-0.862
MCB.TO	-0.86
WE.V	-0.851
HSAV.TO	-0.849
SJR-B.TO	-0.848
HURA.TO	-0.847
DRX.TO	-0.844

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Aptose Biosciences Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-7.58

FY	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-7.58

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.440

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.730

Financial Reports:

No articles found.

Aptose Biosciences Inc

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.